UA74337C2 - Застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину для лікування біполярних розладів та манії - Google Patents

Застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину для лікування біполярних розладів та манії

Info

Publication number
UA74337C2
UA74337C2 UA2001128861A UA2001128861A UA74337C2 UA 74337 C2 UA74337 C2 UA 74337C2 UA 2001128861 A UA2001128861 A UA 2001128861A UA 2001128861 A UA2001128861 A UA 2001128861A UA 74337 C2 UA74337 C2 UA 74337C2
Authority
UA
Ukraine
Prior art keywords
cyanoindol
benzofuran
carbamoyl
butyl
piperazine
Prior art date
Application number
UA2001128861A
Other languages
English (en)
Russian (ru)
Inventor
Герд Бартошік
Крістоф СЕЙФРІД
Амстердам Крістоф Ван
Хеннінг Бьоттчер
Евен Седман
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA74337(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of UA74337C2 publication Critical patent/UA74337C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Винахід стосується нового застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину або його фізіологічно прийнятної солі у виробництві медичних препаратів для лікування біполярних розладів та манії. Переважною сіллю є гідрохлорид 1-[4-5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину.
UA2001128861A 1999-05-27 2000-05-16 Застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину для лікування біполярних розладів та манії UA74337C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27
PCT/EP2000/004376 WO2000072832A2 (en) 1999-05-27 2000-05-16 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts

Publications (1)

Publication Number Publication Date
UA74337C2 true UA74337C2 (uk) 2005-12-15

Family

ID=8238153

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001128861A UA74337C2 (uk) 1999-05-27 2000-05-16 Застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину для лікування біполярних розладів та манії

Country Status (31)

Country Link
US (4) US6900212B1 (uk)
EP (3) EP1185272B1 (uk)
JP (2) JP4884588B2 (uk)
KR (1) KR100683367B1 (uk)
CN (3) CN1679577A (uk)
AR (1) AR024112A1 (uk)
AT (3) ATE263564T1 (uk)
AU (1) AU771778B2 (uk)
BR (1) BR0010948A (uk)
CA (3) CA2615271C (uk)
CY (2) CY1105750T1 (uk)
CZ (1) CZ295623B6 (uk)
DE (3) DE60030338T2 (uk)
DK (3) DK1736158T3 (uk)
ES (3) ES2330774T3 (uk)
HK (1) HK1048444B (uk)
HU (1) HU229059B1 (uk)
IL (2) IL146707A0 (uk)
MX (1) MXPA01012172A (uk)
MY (1) MY135627A (uk)
NO (2) NO322120B1 (uk)
PL (3) PL199650B1 (uk)
PT (3) PT1410800E (uk)
RU (1) RU2237477C2 (uk)
SI (2) SI1185272T1 (uk)
SK (1) SK287851B6 (uk)
TR (1) TR200103361T2 (uk)
TW (1) TW518218B (uk)
UA (1) UA74337C2 (uk)
WO (1) WO2000072832A2 (uk)
ZA (1) ZA200110485B (uk)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) * 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
WO2004082686A2 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
WO2005094896A2 (en) * 2004-03-26 2005-10-13 Baylor University Targeted serotonin reuptake inhibitors
AU2007266890B2 (en) 2006-05-30 2011-02-17 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors
ES2535083T3 (es) 2007-12-20 2015-05-05 Astrazeneca Ab Compuestos de carbamoilo como inhibidores 190 de DGAT1
WO2010146395A1 (en) 2009-06-19 2010-12-23 Astrazeneca Ab Pyrazine carboxamides as inhibitors of dgat1
US8927602B2 (en) * 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012131706A1 (en) 2011-03-20 2012-10-04 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
US9382233B2 (en) 2012-06-13 2016-07-05 Apotex Inc. Forms of vilazodone and processes for the preparation thereof
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
DK2948140T3 (en) 2013-01-22 2017-08-21 Vistagen Therapeutics Inc DOSAGE FORMS AND THERAPEUTIC APPLICATIONS OF L-4-CHLORCYNURENINE
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
EA201792571A1 (ru) * 2015-05-22 2018-06-29 Вистаджен Терапьютикс, Инк. Терапевтическое применение l-4-хлорокинуренина

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612563A3 (en) * 2001-09-11 2009-12-09 JTEKT Corporation Magnetic pulser ring
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
ATE438399T1 (de) 2009-08-15
MXPA01012172A (es) 2002-07-22
DK1410800T3 (da) 2006-12-27
PT1410800E (pt) 2007-01-31
PL199650B1 (pl) 2008-10-31
CN1361692A (zh) 2002-07-31
DE60030338T2 (de) 2007-08-16
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
EP1410800A1 (en) 2004-04-21
CN101869565A (zh) 2010-10-27
SK287851B6 (sk) 2012-01-04
IL146707A (en) 2007-06-03
WO2000072832A2 (en) 2000-12-07
DE60009697D1 (de) 2004-05-13
KR100683367B1 (ko) 2007-02-15
NO322120B1 (no) 2006-08-14
EP1736158B1 (en) 2009-08-05
NO20061562L (no) 2001-11-26
WO2000072832A3 (en) 2001-12-20
HK1048444A1 (en) 2003-04-04
HUP0201275A2 (en) 2002-08-28
ATE337008T1 (de) 2006-09-15
TR200103361T2 (tr) 2002-05-21
US20100063062A1 (en) 2010-03-11
ATE263564T1 (de) 2004-04-15
SI1185272T1 (en) 2004-12-31
CA2372668C (en) 2009-11-03
EP1410800B1 (en) 2006-08-23
EP1736158A2 (en) 2006-12-27
US20080119484A1 (en) 2008-05-22
HK1048444B (zh) 2005-12-09
SI1410800T1 (sl) 2007-02-28
EP1185272B1 (en) 2004-04-07
KR20020008847A (ko) 2002-01-31
NO324230B1 (no) 2007-09-10
ES2330774T3 (es) 2009-12-15
CN1679577A (zh) 2005-10-12
PL200490B1 (pl) 2009-01-30
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
CY1105750T1 (el) 2010-12-22
PT1185272E (pt) 2004-08-31
CY1109472T1 (el) 2012-05-23
CA2372668A1 (en) 2000-12-07
TW518218B (en) 2003-01-21
AU771778B2 (en) 2004-04-01
CZ20014226A3 (cs) 2002-03-13
JP2011148799A (ja) 2011-08-04
NO20015746L (no) 2001-11-26
ES2271707T3 (es) 2007-04-16
SK16462001A3 (sk) 2002-02-05
JP4884588B2 (ja) 2012-02-29
ZA200110485B (en) 2003-06-30
HU229059B1 (en) 2013-07-29
AR024112A1 (es) 2002-09-04
US7371756B2 (en) 2008-05-13
HUP0201275A3 (en) 2004-04-28
MY135627A (en) 2008-05-30
US7642261B2 (en) 2010-01-05
CZ295623B6 (cs) 2005-09-14
CN1198618C (zh) 2005-04-27
DK1736158T3 (da) 2009-11-02
CA2694866A1 (en) 2000-12-07
NO20015746D0 (no) 2001-11-26
IL146707A0 (en) 2002-07-25
DK1185272T3 (da) 2004-08-09
DE60042710D1 (de) 2009-09-17
CA2615271A1 (en) 2000-12-07
JP2003500441A (ja) 2003-01-07
AU5066300A (en) 2000-12-18
EP1736158A3 (en) 2007-01-03
BR0010948A (pt) 2002-04-23
DE60030338D1 (de) 2006-10-05
CA2615271C (en) 2011-02-15
PL199516B1 (pl) 2008-09-30
PL352373A1 (en) 2003-08-25
PT1736158E (pt) 2009-11-11
DE60009697T2 (de) 2005-04-14
RU2237477C2 (ru) 2004-10-10

Similar Documents

Publication Publication Date Title
UA74337C2 (uk) Застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину для лікування біполярних розладів та манії
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
SI0955295T1 (en) Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines
MXPA06001838A (es) Sales de succinato y malonato de la trans-4- ((ir, 3s)-6 -cloro-3- fenilindan -1-il)-1, 2, 2- trimetilpiperazina y su uso como medicamento.
NZ513851A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
HK1016068A1 (en) Use of eliprodil for the manufacture of a medicament for the treatment of ischemic disorders of the retina of the optic nerve
NZ334571A (en) Pharmaceutical composition comprising 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-acetic acid for treating diseases induced by respiratory syncytial virus
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
MEP5608A (xx) Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
EP1062948A4 (en) MEDICINAL PRODUCTS FOR DIASTOLIC HEART DISEASES
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
WO2002044159A3 (en) 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
MXPA04001812A (es) Nueva forma de dosificacion oral de liberacion prolongada.
IL133216A0 (en) 2-ä4-[4(4,5-Dichloro-2-methylimidazol-1-yl) butyl]-1 piperazinylü-5-fluoropyrimidine preparation and therapeutic use
YU17002A (sh) Upotreba deksrazoksana u lečenju psorijaze
MY154535A (en) Succinate and malonate salt of trans-4-((1r,3s)-6-chloro-3-phenylindan-1-y1)-1,2,2-trimethylpiperazine and the use as a medicament
SE0102888D0 (sv) New formulation
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
SE9802119D0 (sv) New use
HRP970701B1 (en) Micro-particulate form of a tetrahydropyridin derivative